Effectiveness of motor-cognitive dual-task exercise via telerehabilitation in Alzheimer's disease
MetadataShow full item record
CitationMENENGİÇ, K. N., YELDAN, İ., ÇINAR, N., & ŞAHİNER, T. (2022). Effectiveness of motor-cognitive dual-task exercise via telerehabilitation in Alzheimer’s disease: An online pilot randomized controlled study. Clinical Neurology and Neurosurgery, 107501.
Objective: It is important to investigate the effectiveness of delivering the rehabilitation service using remote communication technologies, for conditions that face-to-face treatment is not possible. This study aimed to investigate the effectiveness of exercise treatment via home-based telerehabilitation (TR) in Alzheimer's disease (AD). Methods: Twenty participants who were diagnosed as having the early-middle stage of AD were randomized into a TR group and control group. The TR group received real-time motor-cognitive dual-task exercise treatment via video conferencing, and the control group received no intervention for 6 weeks. The primary outcomes were Mini-Mental State Examination, Timed Up&Go Test, and the 5 Times Sit&Stand Test, and the secondary outcomes were One-leg Stance Test (OLST), Katz Activities of Daily Living Scale (Katz-ADL), Functional Independence Measure, Geriatric Depression Scale-Short Form, Beck Anxiety Scale, Zarit Caregiver Burden Inventory (ZCBI) and the Warwick Edinburgh Well-being Scale. Outcomes were measured at baseline and post-treatment. Results: There was a significant difference in the mean change between the groups in favor of the TR group in all primary and secondary outcomes (p < .05), except for the ZCBI and OLST(p > .05). There was no significant difference in the comparison of the primary outcome measures between the groups in post-treatment results (p > .05); significant differences in all secondary outcome measures were observed in favor of the TR group (p < .05), except for the OLST, Katz-ADL, and ZCBI (p > .05). Conclusion: TR may provide a significant change in cognition and mobility, improve functional independence, and caregiver's well-being, and reduce anxiety and depressive symptoms in people with AD. © 2022 Elsevier B.V.